Expanded testing Premier Biotech has a rapidly growing portfolio of drug testing configurations that cover newest trends in drug abuse beyond traditional panels, presenting opportunities to upsell to employers, clinics, and correctional facilities seeking comprehensive toxicology screening.

Strategic acquisitions With seven acquisitions since 2022, including NexScreen, TransMed, and Ntsbiz, there are cross-sell and integration opportunities across acquired entities, enabling bundled solutions and expanded TAM in point-of-care and laboratory testing segments.

Multi-market reach Serving workplace testing, criminal justice, mental health, pain management, primary care, and behavioral health, Premier Biotech can tailor value propositions to each segment, highlighting faster, more accurate results and flexible configurations.

CAP accredited lab Premier Biotech Labs holds CAP Forensic accreditation, which can be leveraged to win contracts with regulated facilities, healthcare providers, and government or corrections agencies that require high-quality forensic toxicology services.

Growth financing Recent funding and alignment partnerships with Align Capital Partners indicate strong financial backing and potential for scale, supporting larger deployments, site expansions, and accelerated go-to-market initiatives.